News & Press

  • Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology (https://www.asco.org/))...

  • Isofol announces that an abstract with new research resultshas been published for this year's ASCO congress in Chicago

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year's annual...

  • Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States...

  • Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels...

  • Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult...

  • Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin®

    Isofol Medical AB (publ) today announce that the company will in the future be adopting the generic name...

  • Isofol reports successful outcome from the scientific advice with the EMA

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines...

  • Isofol’s CEO, directors and employees converts stock - and employee options and subscribe shares for SEK 7 655 136

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated...

  • Positive treatment results with Modufolin® (arfolitixorin) will be published at a cancer congress (ASCO) in the US

    Prior to this year’s Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology...

  • Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin® agreed

    Isofol Medical AB (publ), developing Modufolin®(arfolitixorin) as treatment for advanced colorectal...

  • Isofol reports positive efficacy data for Modufolin® (arfolitixorin) from patients treated for metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, reports efficacy data for Modufolin® (arfolitixorin)...

  • Isofol to present at the 10th Annual Biotech Showcase Conference

  • Isofol announces that an abstract regarding Modufolins® efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018

    Isofol Medical AB (publ) announces that an abstract regarding Modufolins® efficacy in colorectal cancer...

  • ­­­Isofol appoints Gustaf Albèrt as Chief Financial Officer

    Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience...

  • Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities

    Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin®...

  • Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer

    Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation...

  • From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

    Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin®...

  • Isofols appoints Sven Erickson as Chief Commercial Officer

    In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the...

  • Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®

    Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal...

  • Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017

    Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented...

  • Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical

  • Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001

    Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001...

  • New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study

    Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented...

  • Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin® is evaluated in colorectal cancer

    Isofol Medical AB (publ) announced today that the last one of five additional study sites was initiated...

  • Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting

    Isofol Medical AB (publ) announces publication of an abstract regarding failure rate of standard rescue...

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

  • Isofol accepted for presentation of abstract at the 2017 ASCO annual meeting

    Isofol Medical AB (publ) announces that an abstract has been accepted to be presented at the American...

  • Pareto Securities has notified Isofol Medical AB (publ) that stabilisation measures regarding the Company’s shares have been taken

  • Pareto Securities has notified Isofol Medical AB that stabilisation measures regarding the Company’s shares have been taken

  • Isofol has successfully completed the ISO-MTX-003 study in which Modufolin® is evaluated as rescue therapy

  • Isofol’s largest shareholder and co-founder acquires shares in the company

  • Isofol’s Chairman of the Board acquires shares in the company

  • Isofol Medical announces the outcome of the Offering – trading on Nasdaq First North Premier commences today

  • Invitation: Isofol will present it's contemplated IPO in Stockholm on March 29

  • Invitation: Isofol will present it's contemplated IPO in Göteborg on March 22

  • Listing of Isofol Medical on Nasdaq First North Premier and publication of prospectus

  • Isofol announces its intention to list on Nasdaq First North Premier

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED...

  • ISOFOL FILES IMPORTANT NEW US PATENT APPLICATION

  • FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®

    Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational...

  • ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING

    Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting...

  • ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.

    Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with...

  • ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs...